What does elevated parathyroid hormone (PTH) together with elevated uric acid signify?

Elevated PTH with Elevated Uric Acid: Clinical Significance

The combination of elevated PTH and elevated uric acid most commonly signifies primary hyperparathyroidism (PHPT) with associated hyperuricemia, or secondary hyperparathyroidism due to chronic kidney disease (CKD), where both markers are independently elevated due to declining renal function.

Primary Diagnostic Considerations

1. Primary Hyperparathyroidism (PHPT)

The association between PHPT and elevated uric acid is well-established 1, 2. Patients with PHPT have significantly higher serum uric acid levels compared to individuals without hyperparathyroidism, with a mean difference of approximately 65 μmol/L 2. This relationship appears to be independent and bidirectional:

• PTH levels positively correlate with serum uric acid levels 3, 4
• The mechanism involves tubular and intestinal transporters, particularly the ABCG2 transporter, as well as indirect effects mediated by hypercalcemia and inflammatory processes 1
• After adjusting for age, sex, dietary factors, GFR, calcium, phosphorus, and vitamin D, the uric acid difference between lowest and highest PTH quintiles is 19 μM 3

Key diagnostic approach for PHPT:

• Confirm hypercalcemia with inappropriately elevated or normal PTH 5
• Check serum phosphorus (typically low in PHPT) 6
• Measure 25-OH vitamin D levels (deficiency must be corrected before confirming PHPT diagnosis) 7, 5
• Calculate fractional excretion of calcium (FeCa >2% supports PHPT; ≤2% suggests familial hypocalciuric hypercalcemia) 5

2. Secondary Hyperparathyroidism from CKD

CKD is the most critical differential diagnosis because declining kidney function independently elevates both PTH and uric acid 8:

• PTH increases with declining GFR due to hyperphosphatemia, hypocalcemia, reduced 1,25-dihydroxy-vitamin D, and elevated FGF23 8
• Uric acid accumulates as renal clearance declines
• The association between PTH and uric acid is stronger in renally impaired individuals (multivariate uric acid difference of 26 μM vs 15 μM in those with GFR <60 vs ≥60 ml/min/1.73 m²) 3

Diagnostic algorithm for CKD-related secondary hyperparathyroidism:

• Calculate eGFR to assess kidney function
• Check serum calcium (typically low-normal or low in secondary hyperparathyroidism vs elevated in PHPT)
• Measure serum phosphorus (elevated in CKD stages 4-5 vs low in PHPT) 9
• Assess 25-OH vitamin D status 7

3. Hypophosphatemic Disorders

X-linked hypophosphatemia (XLH) and other hereditary hypophosphatemic conditions can present with elevated PTH and may have associated hyperuricemia 7, 6:

• In XLH, 25-67% of patients develop hyperparathyroidism, often normocalcemic 6
• Hypophosphatemia is the defining feature (low serum phosphorus with renal phosphate wasting)
• FGF23 levels are elevated
• Hypercalciuria may be present in certain hereditary forms 6

Clinical Implications and Management Priorities

Cardiovascular and Renal Risk

Both elevated PTH and uric acid independently increase cardiovascular disease risk and CKD progression 10, 1:

• The combination may represent additive or synergistic metabolic dysfunction
• Increased PTH and secondary hyperparathyroidism are independently associated with CKD progression, cardiovascular events, mortality, and fractures 10

Musculoskeletal Manifestations

Gout can occur in PHPT patients, though pseudogout is more common 11:

• Acute gouty arthritis in large joints has been reported in PHPT
• Parathyroidectomy leads to reduction in uric acid levels and improvement in joint manifestations 11
• Serum uric acid levels positively correlate with intact PTH levels 11

Diagnostic Workup Algorithm

Step 1: Assess renal function

• Calculate eGFR
• If eGFR <60 ml/min/1.73 m², secondary hyperparathyroidism from CKD is likely

Step 2: Measure calcium and phosphorus

• Hypercalcemia + hypophosphatemia + elevated PTH = PHPT 5
• Normocalcemia or hypocalcemia + hyperphosphatemia + elevated PTH = secondary hyperparathyroidism from CKD 9
• Normocalcemia + hypophosphatemia + elevated PTH = consider XLH or other hypophosphatemic disorders 6

Step 3: Check vitamin D status

• Vitamin D deficiency elevates PTH and must be corrected before confirming PHPT 8, 7, 5
• Target 25-OH vitamin D >20 ng/ml (50 nmol/L) 7

Step 4: Calculate fractional excretion of calcium (if PHPT suspected)

• FeCa = (urinary calcium × plasma creatinine)/(urinary creatinine × plasma calcium)
• FeCa >2% supports PHPT; ≤2% suggests familial hypocalciuric hypercalcemia 5

Step 5: Consider oral calcium loading test for atypical presentations

• Helps differentiate normocalcemic PHPT from other causes of elevated PTH 5

Common Pitfalls to Avoid

1. Failing to correct vitamin D deficiency before diagnosing PHPT - vitamin D deficiency independently elevates PTH 8, 7, 5

2. Not assessing renal function - CKD is a common cause of both elevated PTH and uric acid, and the association is stronger with declining GFR 3

3. Ignoring calcium and phosphorus patterns - these are critical for distinguishing primary from secondary hyperparathyroidism 9, 5

4. Overlooking medication effects - thiazide diuretics can cause hypercalcemia and hyperuricemia; lithium can elevate PTH 5

5. Assuming hyperuricemia is incidental - the PTH-uric acid association is independent and may reflect shared pathophysiological mechanisms involving metabolic dysfunction 1, 12

Treatment Considerations

For PHPT with hyperuricemia:

• Parathyroidectomy is definitive treatment and leads to reduction in uric acid levels 11
• Screen for hyperuricemia, especially in patients with additional cardiovascular risk factors 1

For CKD-related secondary hyperparathyroidism:

• Target phosphorus control: 3.5-5.5 mg/dL in stage 5 CKD 9
• Dietary phosphate restriction to 800-1000 mg/day when PTH elevated above target 9
• Consider active vitamin D or calcimimetics for PTH control 10
• Monitor both PTH and uric acid as markers of metabolic dysfunction and cardiovascular risk

The UA/Cr ratio may provide additional prognostic information - higher ratios are independently associated with elevated PTH levels even after adjusting for vitamin D, mineral metabolism, and renal function 12, though this requires further validation for clinical use.